Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
about
Glatiramer acetate for multiple sclerosisOptimizing treatment success in multiple sclerosisTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations.(-)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis.A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS PatientsSwitching multiple sclerosis patients with breakthrough disease to second-line therapy.Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.Relapsing-remitting multiple sclerosis: patterns of response to disease-modifying therapies and associated factors: a national survey.Comparative efficacy of switching to natalizumab in active multiple sclerosis.Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetateInterferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational StudyThe Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.Improving outcomes in multiple sclerosis through early diagnosis and effective management.Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Principles of a new treatment algorithm in multiple sclerosis.Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.The transition from first-line to second-line therapy in multiple sclerosis.An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.A method for evaluating treatment switching criteria in multiple sclerosis.Switching therapies in multiple sclerosis.Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial.Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal responseMultiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon
P2860
Q24235498-A94F84D5-37E3-40BC-BDFA-A9F3C7FE95C9Q26771968-1245C7F6-D1F4-400F-83A0-E73E79061374Q26798434-2A7A00DD-D43E-4BCA-B4D6-48EF501146F7Q30993770-A1BA29C9-C228-4690-8662-759906EC3CEAQ33624245-0C18202E-A648-42FE-B177-0FF19DDC0F7FQ33692589-A363E34F-1C42-44F8-8E94-E03A47182DCAQ33736209-AFE9FCA1-582E-40A2-857B-B67AEC4C66A1Q33815455-D79B84EA-FBE6-48B8-B40C-A4362D8B621FQ33830080-46EFA9F3-FDA5-41C1-9543-7650A8301B66Q34459729-F262C878-143A-44FA-AE11-B3E0E0195A3DQ35280670-12B6F161-E850-4E2D-8C19-A7D0464E337DQ35469575-11C35C69-D0C4-4744-81B2-EA7B50E0F162Q35749670-2A34219C-561F-4A3A-B718-E2A7D4E7A83EQ35801041-480BE7B8-A684-40C1-88BB-E272D904819BQ35902505-AD326BE7-DD07-43C3-9950-D4F66A2B506CQ36148189-2AB7934F-DE58-4B64-B5AE-658EA1E1A713Q36643255-A392ECD4-B4A4-4AAB-AEC7-66FF3198E9C5Q36951371-1242723E-E6B9-4CF3-9D38-895D29916323Q36975701-E744430B-48EC-446F-9CED-461D7A2E6DE1Q37849763-9CFF9DE1-E177-4422-98A1-CFEA01BC60F2Q37922644-19C7D47E-3666-40CD-B6D0-696395AE97EFQ37995760-D9F3291C-7C8D-4E98-AD93-321317B475ADQ38873695-8DC0D88F-875A-4022-9AFB-0EDD43475525Q39021942-BF789A67-9EB1-4CE1-9372-DE751EE92F4EQ41014662-69FDBBAF-8A6E-4F96-B9F8-5E0C8542C027Q42217179-542DE24C-2A0F-405B-88A7-7F3FE20FBC9EQ42223350-D3FB8F15-FE1F-4FB1-9056-8EB6829A753AQ42927136-87771821-F038-4BB3-9534-CBD7BDAF4AB4Q45977173-554089D9-CA07-4F9F-9472-9ABA68AC4C2CQ46835552-4FB3F947-4245-4DA7-B238-29531C6F7E12Q48956772-A6E4AEF7-34D8-4716-A015-821B040F29A3Q51089837-FC5751AB-0C28-4742-AAAA-A01550CF6D67Q53998964-6EF2A06B-CBCC-41B2-B1B0-DFDB53EC7D34Q55021339-9963F71E-6EA7-4833-AAD3-ED61FB26112DQ57601861-1F65B72B-68E8-4E34-BF6B-E4E5CB15433DQ59125930-ACE0C94E-F330-4BD3-BD7D-7E48068B3F0E
P2860
Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Switching first-line disease-m ...... -remitting multiple sclerosis.
@ast
Switching first-line disease-m ...... -remitting multiple sclerosis.
@en
Switching first-line disease-m ...... -remitting multiple sclerosis.
@nl
type
label
Switching first-line disease-m ...... -remitting multiple sclerosis.
@ast
Switching first-line disease-m ...... -remitting multiple sclerosis.
@en
Switching first-line disease-m ...... -remitting multiple sclerosis.
@nl
prefLabel
Switching first-line disease-m ...... -remitting multiple sclerosis.
@ast
Switching first-line disease-m ...... -remitting multiple sclerosis.
@en
Switching first-line disease-m ...... -remitting multiple sclerosis.
@nl
P2093
P2860
P356
P1476
Switching first-line disease-m ...... -remitting multiple sclerosis.
@en
P2093
P2860
P356
10.1177/1352458508096687
P577
2008-10-15T00:00:00Z